• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

RBX7455 – A Non-frozen, Lyophilized, Oral Microbiota-based Drug Reduces Clostridrium difficile Infection Recurrence and Restores Patients’ Microbiomes

Sahil Khanna MBBS, Darrell S. Pardi MD, Dale N. Gerding MD, Ken Blount PhD, Courtney Jones, Bill Shannon PhD MBA, Elena Deych MS

Download this poster (2.2 MB)

ACG 2018
October 5-10, 2018, Philadelphia, PA

Background

  • Microbiota-based therapies are demonstrating efficacy in preventing recurrent Clostridium difficile infections (rCDI).
  • RBX7455 is a first-of-its-kind, lyophilized, non-frozen, orallyadministered microbiota-restoring drug candidate that was developed for ease-of-use for rCDI patients.
  • Herein we present clinical safety and efficacy of a Phase 1 investigator-sponsored trial of RBX7455 for preventing rCDI.
  • In addition, we present an accompanying study of microbiome restoration among trial participants.

Clinical Trial Design & Methods

  • Prospective, single-center, open-label Phase 1 investigator-initiated trial (NCT02981316).
  • Inclusion criteria: >18 years old with documentation of recurrent CDI, at least one recurrence after a primary episode and has completed at least two rounds of standard-of-care oral antibiotic therapy; diarrhea resolved, i.e., fewer than 3 watery bowel movements at the time of study enrollment for 48 hours or more; a positive stool test for the presence of C. difficile within 30 days prior to enrollment and standard C. difficile treatment.
  • Exclusion criteria: Known history of continued CDI diarrhea despite antibiotic treatment for CDI; requirement of continuous antibiotic therapy for a condition other than CDI; previous fecal transplant; previous treatment with RBX2660; history of inflammatory bowel disease(ulcerative colitis, Crohn’s disease, microscopic colitis), irritable bowel syndrome, chronic diarrhea, celiac disease; colostomy; evidence of active colitis; intended exposure to antibiotics within 6 months after study enrollment; compromised immune system (white blood cell count <1000 cells/μL); current or expected use of systemic steroids
  • Antibiotics were discontinued 24-48 hours prior to first RBX7455 dose.
  • Participants received 8 RBX7455 capsules per day for four days (Cohort 1), 8 RBX7455 capsules per day for two days (Cohort 2), or 4 RBX7455 capsules per day for two days (Cohort 3).
  • Safety was assessed via a patient diary: in clinic at 1, 4, and 8 weeks and via telephone at 2, 3, between 5-7 weeks, and at 3, 6, 12 and 24 months.
  • Success was defined as the absence of CDI at 8 weeks following completion of the last treatment. Treatment failure is defined as: recurrence of diarrhea <8 weeks after completion of RBX7455 treatment, a positive stool test for C. difficile, a need for retreatment for CDI, and no other cause for diarrhea.
  • Stool samples were collected at baseline and at 7, 30, and 60 days and 24 weeks after treatment.

Microbiome Analysis

  • Nine (9) RBX7455 drug product samples and 89 stool samples from treatment responders were sequenced using a shallow shotgun method (CoreBiome, Minneapolis, MN).
  • Multidimensional scaling analysis was performed on participant and RBX7455 operational taxonomic unit data according to a Bray-Curtis dissimilarity metric with non-metric scaling, and group mean relative taxonomic abundances at the class level were calculated by fitting to a Dirichlet-multinomial distribution.

RBX7455 Prevents rCDI

  • See poster for graph (2.5 MB)

RBX7455 is Well-tolerated

  • See poster for table (2.5 MB)

Demographics

  • See poster for table (2.5 MB)

RBX7455 Restores a Healthier Microbiome Composition

  • See poster for table (2.5 MB)

Conclusions

  • In this open-label, investigator-sponsored Phase 1 study, all RBX7455 dosing regimens were effective at preventing rCDI.
  • The RBX7455 safety profile is consistent with results from other clinical trials of microbiota-based therapies.
  • Microbiota analysis suggests that RBX7455 restores a healthier microbiome composition.

Microbiota Restoration Therapy Posters Posters

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT